In pituitary-derived FSH veterinary injection manufacturing, the API is received as a lyophilized bulk with batch-specific specific activity and water content below 2.0%. The downstream target is a sterile lyophilized vial for intramuscular or subcutaneous administration in cattle, sheep, and goats. The solution before freeze-drying is prepared in an ISO 14644-1:2015 class 5 filling suite; API is dissolved in 10 mM sodium phosphate buffer at pH 7.0, followed by addition of 2.5% w/v mannitol, 1.0% w/v sucrose, and 0.02% w/v polysorbate 20. The solution is filtered through a 0.22 µm PVDF membrane and filled into Type I glass vials with bromobutyl rubber stoppers. Fill volume is adjusted to the batch-specific IU/mg value from the certificate of analysis; because FSH potency is determined by in vivo ovarian weight gain bioassay, the liquid fill mass is fixed by the label claim in international units, not by protein mass alone.

The freeze-drying cycle is built around the collapse boundary of the mannitol-sucrose formulation. Differential scanning calorimetry of the frozen formulation typically shows a collapse temperature between -25°C and -28°C; primary drying shelf temperature is therefore held at -20°C with chamber pressure at 0.200 mbar. The product is ramped from +5°C to -45°C at 0.5°C/min and held for 180 min. An annealing step at -10°C for 120 min promotes mannitol crystallization and reduces vial-to-vial nucleation variability. Primary drying is held for 72 h until the Pirani gauge reading converges with the capacitance manometer; secondary drying is performed at +25°C and 0.100 mbar for 12 h. Residual moisture in the finished cake is controlled to NMT 3.0% by Karl Fischer titration per Ph. Eur. 2.5.32. The same cycle must be challenged at annual load with thermocouples placed in edge and center vials because edge vials can run 2–4°C warmer than center vials in production-scale shelf arrays.

In production, the main failure mode is microcollapse rather than sterilization failure. If the product temperature in any vial exceeds the collapse boundary during primary drying, the cake shrinks, develops a dense skin, and reconstitution time extends beyond 180 s. Intact cake reconstitutes with sterile saline in 30–60 s with opalescence corresponding to the excipient system. Because FSH is heat-labile and aggregates under terminal steam-sterilization conditions, the product is not terminally sterilized; sterility assurance depends on filter integrity testing before and after filling, isolator media-fill qualification, and environmental monitoring under 21 CFR 211.113. Subvisible particle counts are tested after reconstitution by light obscuration per Ph. Eur. 2.9.19. Release limits are informed by the finished-product dossier and apply to every batch regardless of animal species label claim.

Batch-to-batch variability in pituitary-derived FSH arises primarily from glycosylation microheterogeneity in donor glands rather than from the fill-finish line. The formulated solution is therefore standardized on the basis of IU per vial after potency bioassay; HPLC identity and glycan mapping are supportive but do not replace the in vivo ovarian weight gain assay. This creates a manufacturing scheduling constraint: the liquid fill volume is locked only after the potency result of the final bulk solution is available, which can add 24–48 h to campaign lead time when API lots differ in specific activity.

Release testing follows the matrix in Table 1. The terminal lyophilized product is used for superovulation in donor cattle and ewes before embryo recovery, and for estrous synchronization in goats where species-specific labeling exists. The vial is reconstituted immediately before intramuscular injection; extended holding of the reconstituted solution at room temperature beyond 4 h is not recommended because of progressive aggregation and loss of potency. The lyophilized presentation is preferred in most veterinary FSH products because it avoids the more rapid deamidation seen in aqueous solution and allows shipment under 2–8°C cold-chain conditions with wider excursions than a liquid presentation.

What Processing Window Governs a Ready-to-Use FSH Solution in Multi-Dose Vials?

Liquid FSH injection is selected when a veterinary practice requires multiple draws from a single vial across donor animals in a short synchronization window. The formulation is prepared in 10 mM citrate buffer at pH 6.5, with 0.9% w/v sodium chloride for isotonicity, 0.1% w/v polysorbate 80 as stabilizer, and 0.5% w/v benzyl alcohol as antimicrobial preservative. The solution is filtered through a 0.22 µm PVDF membrane and aseptically filled into amber Type I glass vials under ISO 14644-1:2015 class 5 conditions. Peristaltic pumps used for filling are set to low shear, with gentle acceleration and a maximum speed of ≤50 rpm, because FSH is a dimeric glycoprotein that forms subvisible aggregates at air–liquid and silicone–liquid interfaces.

Stability in the liquid state is the controlling process limit. Storage is at 2–8°C in a vertical position to minimize headspace contact; freezing is rejected because the ice–liquid interface accelerates aggregation. Subvisible particles are controlled by Ph. Eur. 2.9.19; soluble aggregates and deamidation products are monitored by size-exclusion HPLC. Multi-dose vials must meet antimicrobial effectiveness testing per Ph. Eur. 5.1.3. Benzyl alcohol is held below 1.0% w/v because higher concentrations can induce subunit dissociation and visible precipitation. The terminal solution is used in porcine and bovine synchronization protocols; once opened, the in-use period is limited to 28 d when stored at 2–8°C, but the acceptable in-use period must be confirmed by the marketing authorization holder. Published stability data for FSH aqueous solutions are more limited than for lyophilized dosage forms, so liquid presentations are not the default format for heat-sensitive veterinary FSH products.

Tablet compression of FSH is a process boundary, not an approved veterinary route of administration. No current Ph. Eur. or USP monograph describes an oral FSH tablet, because the dimeric glycoprotein is rapidly hydrolyzed in simulated gastric fluid at pH 1.2 and further cleaved by intestinal trypsin at pH 6.8. If a feasibility batch is compressed for non-parenteral investigation, a placebo-compatible formulation comprises 60% w/w mannitol, 30% w/w microcrystalline cellulose, 5% w/w crospovidone, 1% w/w sodium stearyl fumarate, and 4% w/w FSH API. Compression is run on a rotary tablet press at 8–12 kN with a target hardness of 50–70 N; the tablet is then enteric-coated with Eudragit L 30 D-55 to delay acid exposure. Enteric coating does not overcome poor intestinal permeability; disintegration testing per Ph. Eur. 2.9.3 provides process information but no systemic bioavailability claim. Batch release includes USP <905> uniformity of dosage units, but no oral dosage form can be approved in target livestock species without an absorption study that has not been published.

Encapsulation in hypromellose capsules offers no additional protection against gastric pepsin compared with tablets. Experimental capsules containing peptide absorption promoters have been described for laboratory rodents, but for veterinary FSH no target-animal oral absorption study supports a capsule label claim. For analytical stability studies only, 25 mg FSH API is blended with 100 mg sodium glycocholate and 200 mg aprotinin in a size 0 HPMC capsule, filled on a tamping-pin capsule machine at 60–70% relative humidity to reduce electrostatic adhesion. The resulting capsule is a potent peptide mixture for laboratory use; it is not a filed veterinary medicinal product under 21 CFR 510 or equivalent marketing authorization. If oral delivery is attempted in a non-registered field setting, the absence of bioavailability data makes the dosage form non-compliant with good veterinary pharmacovigilance practice.

Dry Powder and Granule Intermediates for Isolator-Based Aseptic Filling

Dry powder and granule intermediates for FSH are manufactured only where the final format is a reconstituted injection, because oral powders and granules face the same proteolytic barrier as tablets and capsules. After lyophilization, the cake is milled under dry nitrogen in a pin mill to a controlled particle-size distribution; the fraction below 150 µm is collected and blended with sterile mannitol to adjust fill mass and content uniformity. Where a denser granule is required for high-speed auger filling, mannitol and sucrose are dry-mixed with the API and roller-compacted at 4–6 MPa, then passed through a 1000 µm screen in an isolator maintained at ISO 14644-1:2015 class 5. The granules are filled by vacuum-assisted auger dosing to a target mass variation of ±3%.

Process controls for dry intermediates include loss-on-drying NMT 2.0% by Ph. Eur. 2.2.32, bulk density 0.45–0.65 g/mL, and content uniformity on 10 samples per Ph. Eur. 2.9.40. The filling line is maintained at ≤15% RH and product-contact parts are AISI 316L stainless steel; operators work through isolator gloves to minimize moisture and bioburden. Terminal dry-filled vials are reconstituted in sterile water for injection immediately before use. These dry intermediates are not feed premixes; they are released by sterility test per Ph. Eur. 2.6.1 and endotoxin test per Ph. Eur. 2.6.14, while an oral feed premix would not be required to meet parenteral sterility or endotoxin limits. The equipment path is therefore separate from any oral line.

Medicated feed premix use of FSH is not an authorized application in any major veterinary jurisdiction. A typical calcium carbonate and wheat middlings premix exposed to feed-mill conditioning at 70–80°C and 12–15% moisture would degrade the glycoprotein within minutes; subsequent ruminal and intestinal peptidases remove any residual intact hormone. Published target-animal oral absorption data for FSH premix is limited; therefore no release specification for an oral premix is defined. The same API lot intended for parenteral use must not be diverted to feed premix unless a validated oral absorption study and a CVMP/CVM filing are in place; currently no such filing exists. This terminal boundary distinguishes a parenteral dry-powder intermediate from a feed premix, despite both using the word “powder” in commercial documentation.